EGFR and non-small cell lung carcinoma: This finding also helps to potentially resolve a question raised by our previous observation that TWIST1 could induce resistance in EGFR mutant NSCLC and TWIST1 was increased at the time of resistance in vivo after EGFR TKI treatment [27].